Canada markets open in 4 hours 35 minutes

Canntab Therapeutics Limited (PILL.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.2850-0.0150 (-5.00%)
At close: 01:22PM EDT
Full screen
Previous Close0.3000
Open0.0000
Bid0.2850 x 0
Ask0.3000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume13,668
Market Cap11.078M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.1230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 08, 2016
1y Target EstN/A
  • CNW Group

    Canntab Corporate Update

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing a corporate update to its shareholders and stakeholders. Further to the announcement made by Canntab on April 14, 2022 with respect to our exploration of a variety of alternative business strategies including potential M&A opportunities, as well as identifying and negotiating partnership

  • CNW Group

    CANNTAB ANNOUNCES CHANGE OF AUDITOR

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces that that it has changed its auditor from MNP LLP (the "Former Auditor") to Clearhouse LLP (the "Successor Auditor"). The Former Auditor resigned effective May 27, 2022, at the Company's request, and the Company's board of directors appointed the Successor Auditor to fill the resulting vaca

  • CNW Group

    Canntab Engages Hamish Sutherland as Strategic Advisor

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the Company has engaged Mr. Hamish Sutherland as a strategic business consultant to work with Canntab and develop additional sales and distribution channels for the extensive suite of Canntab's products and to assist Canntab in reaching strategic partnerships in the Cannab